- In May 2024, Novartis made significant strides in chronic myeloid leukemia (CML) treatment by introducing a groundbreaking compound targeting the BCR::ABL1 fusion protein. With successful trial outcomes, this advancement promises to offer improved therapy options for CML patients, building on years of research in the field
- In November 2023, leading patent applicants for tyrosine kinase inhibitors included Seattle Children's Hospital, F. Hoffmann-La Roche, Pfizer, and Arog Pharmaceuticals. Among them, Seattle Children's Hospital stood out for its diversity in patent applications and its broad geographic reach, securing the top spot in this domain
- In June 2022, the European Commission approved capmatinib (Tabrecta), a tyrosine kinase inhibitor, for use as a monotherapy in treating patients with MET exon14 skipping (METex14) altered advanced non-small cell lung cancer (NSCLC). This approval targets patients requiring systemic therapy after prior treatments such as immunotherapy and platinum-based chemotherapy
- In February 2022, Merck's once-daily oral tyrosine kinase inhibitor, TEPMETKO (tepotinib), was approved by the European Commission for monotherapy use in treating adult patients with advanced non-small cell lung cancer (NSCLC), offering a new treatment option for this challenging condition
- In May 2020, Pfizer Oncology reported positive Phase 3 trial results from the JAVELIN Renal 101 study. The combination of avelumab and axitinib demonstrated significant improvements in outcomes for patients with advanced renal cell carcinoma, advancing the field of cancer treatment
